AKT1 and cancer: Since PI3k-Akt signaling is a promising therapeutic target in cancers, a number of inhibitors against PI3K, Akt and/or mTOR have been developed [92], which show significant anti-tumor (including MM) activity, either alone or in combination with other therapeutic agents or radiotherapy.